About Hervolution
Hervolution is a company based in Copenhagen (Denmark) founded in 2018. Hervolution has raised $18.17 million across 2 funding rounds from investors including Serum Institute of India, European Union and EIC Fund. The company has 13 employees. Hervolution offers products and services including Immunotherapy Platform and Pipeline Assets. Hervolution operates in a competitive market with competitors including Ardelyx, VBI Vaccines, HilleVax, DermBiont and Inozyme Pharma, among others.
- Headquarter Copenhagen, Denmark
- Employees 13
- SectorsHealthcare
- Email••••••••
- Website hervolutiontx.com
- Social LinkedIn
- Legal Name Inprother Aps
- Total Equity Funding$18.17M (USD)
in 2 rounds
- Latest Funding Round$11.7M (USD), Series A
Dec 2024
- InvestorsSerum Institute of India
& 2 more
- Employee Count13
Products & Services of Hervolution
Hervolution offers a comprehensive portfolio of products and services, including Immunotherapy Platform and Pipeline Assets.
Engineers therapies targeting HERVs for disease treatment.
Off-the-shelf assets for cancer and metabolic disease interventions.
Funding Insights of Hervolution
Hervolution has successfully raised a total of $18.17M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $11.7 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18.17M
- Total Rounds 2
- Last Round Series A — $11.7M
- First Round $6.47M
(May 2023)
- Investors Count 3
All 2 funding rounds of Hervolution with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $11.7M | Series A | – | Serum Institute of India | |
| May 2023 | $6.47M | Seed | – | EIC Fund | – |
3 investors in total: 3 institutional.
Investors in Hervolution
Hervolution has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Serum Institute of India, European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Vaccines and immuno-biological drugs for infectious diseases are manufactured. | 1966 | seruminstitute.com | Pune, India | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Hervolution
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Hervolution
3 dated milestones of Hervolution across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Hervolution is founded.
- Funding First funding round of $6.5M.
- Funding Latest funding round, Series A, of $11.7M.
Competitors of Hervolution
Hervolution operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ardelyx, VBI Vaccines, HilleVax, DermBiont and Inozyme Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ardelyx.com | 2007 | Fremont, United States | $61.1M | 37 | Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | |
| vbivaccines.com | 2001 | Cambridge, United States | $65.07M | 13 | VBI Vaccines is engaged in developing vaccines and immunotherapeutics. | |
| hillevax.com | 2021 | Boston, United States | $135M | 62 | A norovirus vaccine is developed for infection prevention. | |
| dermbiont.com | 2015 | Melrose, United States | $78.91M | 14 | Microbial therapeutics for skin diseases are developed. | |
| inozyme.com | 2016 | Cambridge, United States | $116.4M | 59 | Developer of treatments for rare and debilitating metabolic diseases | |
| intercell.com | 1998 | Vienna, Austria | $78.62M | – | Vaccines for infectious diseases, including antigens and adjuvants, were developed. | |
| sinovac.com | 2001 | Haidian, China | – | – | Vaccines against various infectious diseases are developed by Sinovac. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| vedantabio.com | 2010 | Cambridge, United States | $350.49M | 71 | Therapeutics for infectious and autoimmune diseases are developed. |
Detailed competitors of Hervolution
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hervolution
Complete news archive for Hervolution
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Hervolution
10 companies that operate in the same segment as Hervolution (Metabolic Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Developer of cortisol modulators for the treatment of various diseases | 1998 | Menlo Park, California, United States | – | USD 761.41 M | 500 | |
Developer of therapies for the treatment of endocrine-related diseases and cancers | 2008 | San Diego, California, United States | USD 103.5 M | USD 1.04 M | 437 | |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | 2009 | Cambridge, Massachusetts, United States | USD 685 M | – | 81 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Solutions for biomarker discovery and diagnostic testing are provided. | 2000 | Morrisville, United States | USD 165.87 M | – | – | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Hervolution
Hervolution was founded in 2018 and raised its 1st funding round 5 years after it was founded.
Hervolution is headquartered in Copenhagen, Denmark.
Hervolution is a funded company, having raised a total of $18.17M across 2 funding rounds to date. The company's 1st funding round was a Seed of $6.47M, raised on May 2023.
Hervolution has 13 employees.
Hervolution was founded in 2018 and is headquartered in Copenhagen, Denmark. Focus is placed on the biotechnology sector, where immunotherapies for cancer treatment are developed. A lead candidate, IPT001, is advanced as a vaccine that employs Adenoviral and RNA vectors. Human Endogenous Retroviruses are targeted as antigens specific to tumors and senescence. Operations involve research into oncology solutions through endogenous viral elements.
Hervolution's top competitors include Ardelyx, HilleVax and VBI Vaccines.
Hervolution offers Immunotherapy Platform and Pipeline Assets.
Hervolution has 3 investors. Key investors include Serum Institute of India, European Union, and EIC Fund.
Hervolution operates through Inprother Aps.